Background:
Although meningiomas are common intracranial tumors, multiple meningiomas (MMs) are rare entities in patients without neurofibromatosis type 2. Previous studies suggest most sporadic MMs are of monoclone in origin.
Objective:
To elucidate the clonal relationship between two sporadic meningiomas from the same patient by using the next-generation sequencing (NGS) platform.
Methods:
Two MMs, located frontally and parietally on the right side, were surgically removed from a 52-year-old male. Pathological examinations and whole exome sequencing were performed on tumor samples, followed by Sanger sequencing validation.
Results:
MMs were diagnosed as secretory and fibrous subtypes, respectively, on histology (WHO grade I) and tumor DNA exhibited distinctive somatic mutation patterns. Specifically, the secretory subtype carried more single nucleotide variant while the fibrous subtype had much higher copy number variation. Besides, the two tumors demonstrated different mutation profiles in predisposing genes and known driver mutations. For example, the secretory subtype had missense mutations in
TRAF7
and
KLF4
, while the fibrous subtype had frameshift deletion of
NF2
gene in addition to copy number loss of
NF2
and
SMARCB1
, genetic events that have already been associated with the development of meningiomas. Significantly mutated gene analysis revealed novel mutations of
LOC729159
in the secretory subtype and
RPGRIP1L
and
DPP6
in the fibrous subtype. Sanger sequencing validated important point mutations in
TRAF7
(c.1678G>A,
p
.G560S),
KLF4
(c.1225A>C,
p
.K409Q) and
CDH11
(c.169T>G,
p
.W57G).
Conclusion:
Our data suggest the two meningiomas might develop independently in this patient and molecular subtyping by NGS is a valuable supplement to conventional pathology. Further study is needed to ascertain whether these novel genetic events are tumorigenic or simply passenger mutations, as well as their clinical implications